Hacia un pancreas artificial ? FDA approves Animas insulin pump, continuous glucose monitor combo device

Publicado por en 2 Dic, 2014 en Noticias | Sin comentarios

Hacia un pancreas artificial ? FDA approves Animas insulin pump, continuous glucose monitor combo device

The U.S. Food and Drug Administration (FDA) has approved the Animas Vibe, a combination insulin pump and continuous glucose monitor (CGM). It allows patients with Type 1 diabetes to monitor blood glucose levels mostly without a finger stick and adjust insulin delivery based on that data. Animas is a Johnson & Johnson company.

This is one step toward the widespread availability of an artificial pancreas , which would deliver multiple hormones such as insulin and glucagon automatically and effectively enough to closely mimic the natural way the body maintains blood sugar levels. A recent study published in The Lancet found that an artificial pancreas is more effective than conventional treatment for Type 1 diabetes with a patient-controlled insulin pump.

The Animas Vibe integrates Dexcom’s Platinum sensing CGM technology. The latest glucose readings are visible on the built-in device screen, as are glucose level trends over time. The CGM measures glucose levels every 5 minutes. The device offers insulin dosing in increments of 0.025 U/hr; patients can adjust dosing based on insulin-to-carb ratios, insulin sensitivity and blood glucose targets.

Dejar una Respuesta

Tu dirección de correo electrónico no será publicada.

Uso de cookies

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.plugin cookies

ACEPTAR
Aviso de cookies